Status:
COMPLETED
Clinical Safety of a Novel Milk Protein Peptide
Lead Sponsor:
Ambryx Biotechnology
Collaborating Sponsors:
Texas A&M University
Baylor University
Conditions:
Drug Safety
Eligibility:
All Genders
35-60 years
Phase:
PHASE1
Brief Summary
Background: A novel milk peptide has been shown in laboratory setting to have natural anti-cancer properties and extend lifespan and improve metabolism in animal models. The purpose of this study was ...
Detailed Description
The study was conducted as a randomized, double-blind, placebo-controlled clinical trial in a university research setting. Healthy volunteers were randomly assigned to ingest in a double-blind and ran...
Eligibility Criteria
Inclusion
- Healthy subjects with body mass index between 27-40.
Exclusion
- have any metabolic disorders including known electrolyte abnormalities, heart disease, arrhythmias, diabetes, thyroid disease or hypogonadism; a history of hypertension, hepatorenal, musculoskeletal, autoimmune, or neurologic disease; if they are taking thyroid, hyperlipidemic, hypoglycemic, anti-hypertensive, or androgenic medications;
- have milk allergies
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2007
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT01412658
Start Date
November 1 2006
End Date
February 1 2007
Last Update
August 9 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baylor University Center for Exercise, Nutrition, and Preventive Health Research
Waco, Texas, United States, 76706